Achieve Life Sciences Leads the Charge in Addressing the Growing Public Health Crisis: A New Era for Smoking and Vaping Cessation
Achieve Life Sciences, a mission-driven company dedicated to developing innovative treatments for smoking and vaping cessation, has made significant strides in addressing the growing public health crisis. In its Q1 2026 earnings conference call, the company's new CEO, Dr. Andrew Goldberg, emphasized the importance of filling the gap between patient need and available solutions.
With nearly 50 million adults in the United States using nicotine, approximately 25 million being smokers, and 18 million vapers, the scale of this problem is staggering. Despite the majority wanting to quit, most fail due to current treatment options falling short. Dr. Goldberg highlighted that there has not been a new FDA-approved smoking cessation therapy in over two decades, and no approved therapy for vaping cessation exists.
The company's CEO expressed conviction in their opportunity to champion a category-defining public health intervention, citing the strength of the clinical data and favorable tolerability profile of their treatment. This mission-driven approach is crucial in addressing the preventable deaths caused by smoking and the risks associated with vaping.
Under Dr. Goldberg's leadership, Achieve Life Sciences has made notable progress. The company recently appointed three new board members: Chris Martin, Dr. Lucian Iancovici, and Dr. Aaron Royston. This addition brings deep expertise in commercial execution, company scaling, investing, and board governance to the team.
Chris Martin's experience in leading the launch of Ohtuvayre, a widely regarded successful pulmonary launch, will undoubtedly benefit Achieve Life Sciences as they navigate their own commercial journey. Dr. Iancovici and Dr. Royston bring extensive knowledge in guiding companies through FDA approval, further solidifying the company's foundation for success.
The announcement of two key leaders from Verona joining Achieve Life Sciences' commercial team is a significant step forward. With these new additions, the company is poised to make significant strides in addressing the public health crisis caused by smoking and vaping.
